Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches

Psoriasis is an immune-mediated inflammatory disease, with a chronic relapsing-remitting course, which affects 2–3% of the worldwide population. The progressive acquisitions of the inflammatory pathways involved in the development of psoriasis have led to the identification of the key molecules of t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna Campanati, Andrea Marani, Emanuela Martina, Federico Diotallevi, Giulia Radi, Annamaria Offidani
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	psoriasis immune-mediated skin diseases therapy pathophysiology Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/16c73e2b3e974af0b68bc99a31453b9d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:16c73e2b3e974af0b68bc99a31453b9d
record_format	dspace
spelling	oai:doaj.org-article:16c73e2b3e974af0b68bc99a31453b9d2021-11-25T16:48:24ZPsoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches10.3390/biomedicines91115112227-9059https://doaj.org/article/16c73e2b3e974af0b68bc99a31453b9d2021-10-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1511https://doaj.org/toc/2227-9059Psoriasis is an immune-mediated inflammatory disease, with a chronic relapsing-remitting course, which affects 2–3% of the worldwide population. The progressive acquisitions of the inflammatory pathways involved in the development of psoriasis have led to the identification of the key molecules of the psoriatic inflammatory cascade. At the same time, psoriasis therapy has radically evolved with the introduction of target molecules able to modify the natural history of the disease, acting specifically on these inflammatory pathways. For these reasons, biologics have been demonstrated to be drugs able to change the disease’s natural history, as they reduce the inflammatory background to avoid irreversible organ damage and prevent systemic complications. However, several issues related to the use of biologics in patients with systemic comorbidities, remain open. All these data reflect the extraordinary potentiality of biologics, but also the unmet medical need to improve our knowledge on the long-term risk related to continuous use of these drugs, and their administration in special populations. This narrative review aims to highlight both the efficacy and safety profile of biologics in psoriasis, starting from pathophysiology and moving towards their clinical application.Anna CampanatiAndrea MaraniEmanuela MartinaFederico DiotalleviGiulia RadiAnnamaria OffidaniMDPI AGarticlepsoriasisimmune-mediated skin diseasestherapypathophysiologyBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1511, p 1511 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	psoriasis immune-mediated skin diseases therapy pathophysiology Biology (General) QH301-705.5
spellingShingle	psoriasis immune-mediated skin diseases therapy pathophysiology Biology (General) QH301-705.5 Anna Campanati Andrea Marani Emanuela Martina Federico Diotallevi Giulia Radi Annamaria Offidani Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches
description	Psoriasis is an immune-mediated inflammatory disease, with a chronic relapsing-remitting course, which affects 2–3% of the worldwide population. The progressive acquisitions of the inflammatory pathways involved in the development of psoriasis have led to the identification of the key molecules of the psoriatic inflammatory cascade. At the same time, psoriasis therapy has radically evolved with the introduction of target molecules able to modify the natural history of the disease, acting specifically on these inflammatory pathways. For these reasons, biologics have been demonstrated to be drugs able to change the disease’s natural history, as they reduce the inflammatory background to avoid irreversible organ damage and prevent systemic complications. However, several issues related to the use of biologics in patients with systemic comorbidities, remain open. All these data reflect the extraordinary potentiality of biologics, but also the unmet medical need to improve our knowledge on the long-term risk related to continuous use of these drugs, and their administration in special populations. This narrative review aims to highlight both the efficacy and safety profile of biologics in psoriasis, starting from pathophysiology and moving towards their clinical application.
format	article
author	Anna Campanati Andrea Marani Emanuela Martina Federico Diotallevi Giulia Radi Annamaria Offidani
author_facet	Anna Campanati Andrea Marani Emanuela Martina Federico Diotallevi Giulia Radi Annamaria Offidani
author_sort	Anna Campanati
title	Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches
title_short	Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches
title_full	Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches
title_fullStr	Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches
title_full_unstemmed	Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches
title_sort	psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/16c73e2b3e974af0b68bc99a31453b9d
work_keys_str_mv	AT annacampanati psoriasisasanimmunemediatedandinflammatorysystemicdiseasefrompathophysiologytonoveltherapeuticapproaches AT andreamarani psoriasisasanimmunemediatedandinflammatorysystemicdiseasefrompathophysiologytonoveltherapeuticapproaches AT emanuelamartina psoriasisasanimmunemediatedandinflammatorysystemicdiseasefrompathophysiologytonoveltherapeuticapproaches AT federicodiotallevi psoriasisasanimmunemediatedandinflammatorysystemicdiseasefrompathophysiologytonoveltherapeuticapproaches AT giuliaradi psoriasisasanimmunemediatedandinflammatorysystemicdiseasefrompathophysiologytonoveltherapeuticapproaches AT annamariaoffidani psoriasisasanimmunemediatedandinflammatorysystemicdiseasefrompathophysiologytonoveltherapeuticapproaches
_version_	1718412941028491264

Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches

Ejemplares similares